Table 2.
Baseline characteristics of patients entering TRIUMPH13
| Characteristic | Inhaled TRE (n = 115) | Placebo (n = 120) | P value |
|---|---|---|---|
| Age, years | 55 (20–75) | 52 (18–75) | 0.056 |
| Male/female | 22/93 | 22/98 | 0.88 |
| PAH etiology | |||
| PAH or familial | 64 (56) | 67 (56) | 0.60 |
| CVD | 40 (35) | 37 (31) | |
| Other | 11 (9) | 16 (13) | |
| Background PAH therapy | |||
| Bosentan | 77 (67) | 88 (73) | 0.29 |
| Sildenafil | 38 (33) | 32 (27) | |
| Time on background therapy weeks | |||
| Bosentan | 99 ± 79 | 90 ± 75 | 0.62 |
| Sildenafil | 65 ± 60 | 77 ± 69 | 0.44 |
| Baseline NYHA II/IV | 112/3 | 118/2 | 0.62 |
| Baseline 6MWD, meters | 346 ± 63 | 351 ± 69 | 0.50 |
Notes: Values are mean (range), n, n (%), or mean ± SD.
Abbreviations: 6MWD, six-minute walk distance; CVD, collagen vascular disease; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; SD, standard deviation; TRE, treprostinil.